JP2014012688A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2014012688A5 JP2014012688A5 JP2013168325A JP2013168325A JP2014012688A5 JP 2014012688 A5 JP2014012688 A5 JP 2014012688A5 JP 2013168325 A JP2013168325 A JP 2013168325A JP 2013168325 A JP2013168325 A JP 2013168325A JP 2014012688 A5 JP2014012688 A5 JP 2014012688A5
- Authority
- JP
- Japan
- Prior art keywords
- nucleic acid
- seq
- sequence
- recombinantly expressed
- heavy chain
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000007523 nucleic acids Chemical class 0.000 claims 16
- 102000039446 nucleic acids Human genes 0.000 claims 16
- 108020004707 nucleic acids Proteins 0.000 claims 16
- 102000003735 Mesothelin Human genes 0.000 claims 1
- 108090000015 Mesothelin Proteins 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US66017705P | 2005-03-10 | 2005-03-10 | |
| US60/660,177 | 2005-03-10 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011290449A Division JP5378497B2 (ja) | 2005-03-10 | 2011-12-29 | 抗メソテリン抗体 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2014012688A JP2014012688A (ja) | 2014-01-23 |
| JP2014012688A5 true JP2014012688A5 (enExample) | 2014-06-19 |
| JP5788443B2 JP5788443B2 (ja) | 2015-09-30 |
Family
ID=36992268
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2008500966A Active JP4949373B2 (ja) | 2005-03-10 | 2006-03-09 | 抗メソテリン抗体 |
| JP2011290449A Active JP5378497B2 (ja) | 2005-03-10 | 2011-12-29 | 抗メソテリン抗体 |
| JP2013168325A Active JP5788443B2 (ja) | 2005-03-10 | 2013-08-13 | 抗メソテリン抗体 |
Family Applications Before (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2008500966A Active JP4949373B2 (ja) | 2005-03-10 | 2006-03-09 | 抗メソテリン抗体 |
| JP2011290449A Active JP5378497B2 (ja) | 2005-03-10 | 2011-12-29 | 抗メソテリン抗体 |
Country Status (7)
| Country | Link |
|---|---|
| US (5) | US7592426B2 (enExample) |
| EP (2) | EP2322560B1 (enExample) |
| JP (3) | JP4949373B2 (enExample) |
| AU (2) | AU2006223301B2 (enExample) |
| CA (1) | CA2600505C (enExample) |
| ES (2) | ES2429340T3 (enExample) |
| WO (1) | WO2006099141A2 (enExample) |
Families Citing this family (85)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2007500508A (ja) * | 2003-07-29 | 2007-01-18 | モルフォテック、インク． | 抗体とエフェクター機能が増強された遺伝子組み換え抗体を作成する方法 |
| US20050232919A1 (en) * | 2004-02-12 | 2005-10-20 | Morphotek, Inc. | Monoclonal antibodies that specifically block biological activity of a tumor antigen |
| AU2006223301B2 (en) * | 2005-03-10 | 2010-11-04 | Eisai, Inc. | Anti-mesothelin antibodies |
| US20060239910A1 (en) * | 2005-04-22 | 2006-10-26 | Morphotek Inc. | Antibodies with immune effector activity and that internalize in folate receptor alpha-positive cells |
| KR100694508B1 (ko) * | 2005-05-24 | 2007-03-13 | 울산대학교 산학협력단 | Ｈｂｂｋ４항체를 포함하는 암 질환 치료용 약학조성물및 이를 이용한 암의 면역치료 방법 |
| US7943133B2 (en) | 2006-02-02 | 2011-05-17 | Boston Biocom Llc | Mesothelin antibody protein fusions and methods of use |
| US7795411B2 (en) * | 2006-10-05 | 2010-09-14 | Fred Hutchinson Cancer Research Center | Vectors for expressing in vivo biotinylated recombinant proteins |
| BRPI0717964A2 (pt) * | 2006-11-02 | 2013-12-17 | Acceleron Pharma Inc | Receptor e antagonistas de ligante da alk1 e usos dos mesmos. |
| HRP20150074T1 (hr) | 2007-10-01 | 2015-03-13 | Bristol-Myers Squibb Company | Humana antitijela koja se vežu za mezotelin i njihove uporabe |
| MX2010005603A (es) | 2007-11-26 | 2010-08-02 | Bayer Schering Pharma Ag | Anticuerpos antimesotelina y usos de los mismos. |
| US8357783B2 (en) | 2008-03-27 | 2013-01-22 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Human anti-mesothelin monoclonal antibodies |
| JP2010014691A (ja) * | 2008-06-20 | 2010-01-21 | Igaku Seibutsugaku Kenkyusho:Kk | 腹水中のメソテリン及び／又は巨核球増強因子を検出するための方法、キット、試薬及び装置 |
| US8460660B2 (en) * | 2009-03-24 | 2013-06-11 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Anti-mesothelin antibodies |
| UY32560A (es) * | 2009-04-29 | 2010-11-30 | Bayer Schering Pharma Ag | Inmunoconjugados de antimesotelina y usos de los mismos |
| HRP20180340T1 (hr) * | 2010-03-30 | 2018-03-23 | Janssen Biotech, Inc. | Humanizirana il-25 protutijela |
| EP3296321B1 (en) * | 2010-12-20 | 2020-07-15 | F. Hoffmann-La Roche AG | Anti-mesothelin antibodies and immunoconjugates |
| US10233240B1 (en) * | 2011-04-18 | 2019-03-19 | The Regents Of The University Of California | Methods for treating cholestatic liver fibrosis |
| WO2012154530A1 (en) | 2011-05-06 | 2012-11-15 | The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Recombinant immunotoxin targeting mesothelin |
| AU2013221585B2 (en) * | 2012-02-17 | 2017-03-30 | Seagen Inc. | Antibodies to integrin alphavbeta6 and use of same to treat cancer |
| WO2013142300A2 (en) * | 2012-03-20 | 2013-09-26 | Biogen Idec Ma Inc. | Jcv neutralizing antibodies |
| TR201909801T4 (tr) | 2012-03-20 | 2019-07-22 | Biogen Ma Inc | JCV nötrleştirici antikorlar. |
| EP2828290B1 (en) | 2012-03-23 | 2018-08-15 | The United States of America, represented by the Secretary, Department of Health and Human Services | Anti-mesothelin chimeric antigen receptors |
| US20140004121A1 (en) | 2012-06-27 | 2014-01-02 | Amgen Inc. | Anti-mesothelin binding proteins |
| AU2013306076B2 (en) * | 2012-08-21 | 2018-01-25 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Mesothelin domain-specific monoclonal antibodies and use thereof |
| MX2017006571A (es) | 2014-11-20 | 2017-09-29 | Hoffmann La Roche | Moleculas de union a antigeno biespecificas activadoras de celulas t. |
| PL3221357T3 (pl) | 2014-11-20 | 2020-11-02 | F. Hoffmann-La Roche Ag | Wspólne łańcuchy lekkie i sposoby zastosowania |
| US11161907B2 (en) | 2015-02-02 | 2021-11-02 | Novartis Ag | Car-expressing cells against multiple tumor antigens and uses thereof |
| DK3298033T4 (da) | 2015-05-18 | 2023-10-02 | Tcr2 Therapeutics Inc | Sammensætninger og medicinske anvendelser til tcr-reprogrammering under anvendelse af fusionsproteiner |
| CA2996060A1 (en) * | 2015-08-21 | 2017-03-02 | Carsgen Therapeutics, Ltd | Fully human anti-mesothelin antibodies and immune effector cells targeting mesothelin |
| KR101782487B1 (ko) * | 2015-09-24 | 2017-09-27 | 재단법인 목암생명과학연구소 | 신규 항-메소텔린 항체 및 이를 포함하는 조성물 |
| EP3356417A1 (en) * | 2015-10-02 | 2018-08-08 | H. Hoffnabb-La Roche Ag | Bispecific t cell activating antigen binding molecules binding mesothelin and cd3 |
| MX389194B (es) | 2015-10-06 | 2025-03-20 | Univ Minnesota | Compuestos terapéuticos y métodos. |
| CN109072195A (zh) | 2015-12-30 | 2018-12-21 | 诺华股份有限公司 | 具有增强功效的免疫效应细胞疗法 |
| KR20180118175A (ko) | 2016-03-04 | 2018-10-30 | 노파르티스 아게 | 다중 키메라 항원 수용체 (car) 분자를 발현하는 세포 및 그에 따른 용도 |
| MX2018011542A (es) | 2016-03-22 | 2019-02-07 | Hoffmann La Roche | Moleculas biespecificas de celulas t activadas por proteasas. |
| CN108884170A (zh) * | 2016-03-22 | 2018-11-23 | 豪夫迈·罗氏有限公司 | 蛋白酶活化的t细胞双特异性分子 |
| US11549099B2 (en) | 2016-03-23 | 2023-01-10 | Novartis Ag | Cell secreted minibodies and uses thereof |
| PL3443096T3 (pl) | 2016-04-15 | 2023-06-19 | Novartis Ag | Kompozycje i sposoby do selektywnej ekspresji chimerycznych receptorów antygenowych |
| CA3019841A1 (en) * | 2016-04-29 | 2017-11-02 | The Board Of Trustees Of The Leland Stanford Junior University | Methods and compositions for the prevention and treatment of surgical adhesions |
| BR112018074453A2 (pt) | 2016-05-27 | 2019-03-19 | Abbvie Biotherapeutics Inc. | proteínas de ligação biespecíficas ligando uma protéina imunomoduladora e um antígeno tumoral |
| WO2017220555A1 (en) | 2016-06-20 | 2017-12-28 | F-Star Beta Limited | Lag -3 binding members |
| GB201612520D0 (en) | 2016-07-19 | 2016-08-31 | F-Star Beta Ltd | Binding molecules |
| JP2019527696A (ja) | 2016-08-01 | 2019-10-03 | ノバルティス アーゲー | プロｍ２マクロファージ分子の阻害剤と組み合わせてキメラ抗原受容体を用いる癌の処置 |
| JP7109789B2 (ja) | 2016-08-02 | 2022-08-01 | ティーシーアール２ セラピューティクス インク． | 融合タンパク質を使用したｔｃｒの再プログラム化のための組成物及び方法 |
| CA3036745A1 (en) | 2016-10-07 | 2018-04-12 | TCR2 Therapeutics Inc. | Compositions and methods for t-cell receptors reprogramming using fusion proteins |
| CA3044593A1 (en) | 2016-11-22 | 2018-05-31 | TCR2 Therapeutics Inc. | Compositions and methods for tcr reprogramming using fusion proteins |
| MA46952A (fr) | 2016-12-01 | 2019-10-09 | Regeneron Pharma | Anticorps anti-pd-l1 radiomarqués pour imagerie immuno-pet |
| US11535662B2 (en) | 2017-01-26 | 2022-12-27 | Novartis Ag | CD28 compositions and methods for chimeric antigen receptor therapy |
| EP3638295A1 (en) | 2017-06-13 | 2020-04-22 | TCR2 Therapeutics Inc. | Compositions and methods for tcr reprogramming using fusion proteins |
| ES3024433T3 (en) | 2017-12-19 | 2025-06-04 | F Star Therapeutics Ltd | Fc binding fragments comprising a pd-l1 antigen-binding site |
| WO2019210153A1 (en) | 2018-04-27 | 2019-10-31 | Novartis Ag | Car t cell therapies with enhanced efficacy |
| WO2019213282A1 (en) | 2018-05-01 | 2019-11-07 | Novartis Ag | Biomarkers for evaluating car-t cells to predict clinical outcome |
| WO2019227003A1 (en) | 2018-05-25 | 2019-11-28 | Novartis Ag | Combination therapy with chimeric antigen receptor (car) therapies |
| EP3802825A1 (en) | 2018-06-08 | 2021-04-14 | Intellia Therapeutics, Inc. | Compositions and methods for immunooncology |
| JP2021527706A (ja) * | 2018-06-18 | 2021-10-14 | アンウィタ バイオサイエンシス， インク． | 抗メソテリンコンストラクト及びその使用 |
| AR116109A1 (es) | 2018-07-10 | 2021-03-31 | Novartis Ag | Derivados de 3-(5-amino-1-oxoisoindolin-2-il)piperidina-2,6-diona y usos de los mismos |
| GB201811408D0 (en) | 2018-07-12 | 2018-08-29 | F Star Beta Ltd | CD137 Binding Molecules |
| GB201811450D0 (en) | 2018-07-12 | 2018-08-29 | F Star Delta Ltd | Mesothelin and CD137 binding molecules |
| GB201811403D0 (en) | 2018-07-12 | 2018-08-29 | F Star Beta Ltd | Antibody molecules |
| ES3044118T3 (en) | 2018-07-12 | 2025-11-26 | Invox Pharma Ltd | Antibody molecules that bind cd137 and ox40 |
| GB201811415D0 (en) | 2018-07-12 | 2018-08-29 | F Star Beta Ltd | Anti-Mesothelin Anti bodies |
| GB201811410D0 (en) | 2018-07-12 | 2018-08-29 | F Star Beta Ltd | OX40 Binding molecules |
| CA3106046A1 (en) | 2018-07-12 | 2020-01-16 | F-Star Beta Limited | Antibody molecules that bind pd-l1 and cd137 |
| TW202026006A (zh) | 2018-08-30 | 2020-07-16 | 美商Ｔｃｒ２療法股份有限公司 | 使用融合蛋白進行tcr再程式化之組成物及方法 |
| US12331320B2 (en) | 2018-10-10 | 2025-06-17 | The Research Foundation For The State University Of New York | Genome edited cancer cell vaccines |
| WO2020081841A1 (en) | 2018-10-19 | 2020-04-23 | Regents Of The University Of Minnesota | Nk engager molecules and methods of use thereof |
| WO2020092631A1 (en) * | 2018-10-31 | 2020-05-07 | Fred Hutchinson Cancer Research Center | Compositions and methods for detecting and treating cancers characterized by expression of mesothelin |
| US20240245670A1 (en) | 2018-12-20 | 2024-07-25 | Novartis Ag | Dosing regimen and pharmaceutical combination comprising 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives |
| CN109705219B (zh) * | 2019-01-08 | 2020-11-13 | 上海霖科生物科技有限公司 | 与间皮素结合的单克隆抗体及其制备方法 |
| EP3924054B1 (en) | 2019-02-15 | 2025-04-02 | Novartis AG | 3-(1-oxo-5-(piperidin-4-yl)isoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof |
| EP3924055B1 (en) | 2019-02-15 | 2024-04-03 | Novartis AG | Substituted 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof |
| EP3986474A1 (en) * | 2019-06-19 | 2022-04-27 | Silverback Therapeutics, Inc. | Anti-mesothelin antibodies and immunoconjugates thereof |
| US11827709B2 (en) | 2019-12-05 | 2023-11-28 | Seagen Inc. | Anti-AVB6 antibodies and antibody-drug conjugates |
| CA3164129A1 (en) | 2019-12-20 | 2021-06-24 | Amgen Inc. | Mesothelin-targeted cd40 agonistic multispecific antibody constructs for the treatment of solid tumors |
| KR20220116522A (ko) | 2019-12-20 | 2022-08-23 | 노파르티스 아게 | 증식성 질환의 치료를 위한 항-tgf-베타 항체 및 체크포인트 억제제의 용도 |
| CA3185455A1 (en) | 2020-06-11 | 2021-12-16 | Novartis Ag | Zbtb32 inhibitors and uses thereof |
| CA3182346A1 (en) | 2020-06-23 | 2021-12-30 | Novartis Ag | Dosing regimen comprising 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives |
| CN116134027B (zh) | 2020-08-03 | 2025-01-24 | 诺华股份有限公司 | 杂芳基取代的3-(1-氧代异吲哚啉-2-基)哌啶-2,6-二酮衍生物及其用途 |
| TW202304979A (zh) | 2021-04-07 | 2023-02-01 | 瑞士商諾華公司 | 抗ＴＧＦβ抗體及其他治療劑用於治療增殖性疾病之用途 |
| TW202321296A (zh) | 2021-10-06 | 2023-06-01 | 美商鏈接免疫療法公司 | 抗間皮素抗原結合分子及其用途 |
| WO2023214325A1 (en) | 2022-05-05 | 2023-11-09 | Novartis Ag | Pyrazolopyrimidine derivatives and uses thereof as tet2 inhibitors |
| WO2024102954A1 (en) | 2022-11-10 | 2024-05-16 | Massachusetts Institute Of Technology | Activation induced clipping system (aics) |
| WO2024226827A2 (en) | 2023-04-25 | 2024-10-31 | Arsenal Biosciences, Inc. | Novel receptors for transcription regulation |
| AU2024276994A1 (en) | 2023-05-24 | 2025-10-23 | Kumquat Biosciences Inc. | Heterocyclic compounds and uses thereof |
| WO2025235862A1 (en) | 2024-05-10 | 2025-11-13 | Inndura Therapeutics Inc. | A modified immune cell receptor comprising a target-binding domain and the extracellular domain of cd16a |
Family Cites Families (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4694778A (en) | 1984-05-04 | 1987-09-22 | Anicon, Inc. | Chemical vapor deposition wafer boat |
| US4851332A (en) | 1985-04-01 | 1989-07-25 | Sloan-Kettering Institute For Cancer Research | Choriocarcinoma monoclonal antibodies and antibody panels |
| GB8607679D0 (en) | 1986-03-27 | 1986-04-30 | Winter G P | Recombinant dna product |
| IL162181A (en) | 1988-12-28 | 2006-04-10 | Pdl Biopharma Inc | A method of producing humanized immunoglubulin, and polynucleotides encoding the same |
| US5789650A (en) * | 1990-08-29 | 1998-08-04 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
| JP2660241B2 (ja) * | 1990-10-12 | 1997-10-08 | アメリカ合衆国 | モノクロナール抗体 |
| US5646253A (en) * | 1994-03-08 | 1997-07-08 | Memorial Sloan-Kettering Cancer Center | Recombinant human anti-LK26 antibodies |
| US6074643A (en) | 1993-09-09 | 2000-06-13 | Cli Oncology, Inc. | Site-directed chemotherapy of metastases |
| US6191268B1 (en) * | 1993-12-17 | 2001-02-20 | Dana-Farber Cancer Institute | Compositions and methods relating to DNA mismatch repair genes |
| CA2182206A1 (en) * | 1994-01-27 | 1995-08-03 | William A. Haseltine | Human dna mismatch repair proteins |
| DE19513676A1 (de) * | 1995-04-11 | 1996-10-17 | Behringwerke Ag | Cytoplasmatische Expression von Antikörpern, Antikörperfragmenten und Antikörperfragmentfusionsmolekülen in E.coli |
| DE19541844C1 (de) * | 1995-11-09 | 1997-07-24 | Gsf Forschungszentrum Umwelt | Verfahren zur Herstellung von menschlichen Antikörpern und deren Verwendung |
| CA2241604C (en) | 1996-01-05 | 2010-03-30 | Ira Pastan | Mesothelium antigen and methods and kits for targeting it |
| BR9708910A (pt) | 1996-05-04 | 1999-08-03 | Zeneca Ltd | Anticorpo conjugado sequência de polinucleotídeos vetor célula hospedeira hibridoma composição farmacêutica processos para fabricar um anticorpo ou um conjugado e para tratar um humano ou animal em necessidade deste tratamento |
| WO1999009956A1 (en) | 1997-08-29 | 1999-03-04 | Corixa Corporation | Rapid release encapsulated bioactive agents for inducing or potentiating an immune response and methods of using thereof |
| EP1025230B1 (en) | 1997-12-01 | 2006-02-08 | THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES | ANTIBODIES, INCLUDING Fv MOLECULES, AND IMMUNOCONJUGATES HAVING HIGH BINDING AFFINITY FOR MESOTHELIN AND METHODS FOR THEIR USE |
| US6809184B1 (en) * | 1997-12-01 | 2004-10-26 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Antibodies, including FV molecules, and immunoconjugates having high binding affinity for mesothelin and methods for their use |
| US6146894A (en) * | 1998-04-14 | 2000-11-14 | The Johns Hopkins University | Method for generating hypermutable organisms |
| US7745159B2 (en) * | 1999-02-26 | 2010-06-29 | Nathalie B Scholler | Methods and compositions for diagnosing carcinomas |
| US6365410B1 (en) * | 1999-05-19 | 2002-04-02 | Genencor International, Inc. | Directed evolution of microorganisms |
| US7081518B1 (en) * | 1999-05-27 | 2006-07-25 | The United States Of America As Represented By The Department Of Health And Human Services | Anti-mesothelin antibodies having high binding affinity |
| AU2001275267A1 (en) | 2000-06-05 | 2001-12-17 | Corixa Corporation | Leader peptides for enhancing secretion of recombinant protein from a host cell |
| US6808894B1 (en) * | 2000-11-07 | 2004-10-26 | Morphotek, Inc. | Methods for generating genetically altered antibody producing cell lines with improved antibody characteristics |
| JP5036119B2 (ja) | 2001-01-15 | 2012-09-26 | モーフオテク・インコーポレーテツド | ミスマッチ修復の化学阻害剤 |
| US20030087250A1 (en) | 2001-03-14 | 2003-05-08 | Millennium Pharmaceuticals, Inc. | Nucleic acid molecules and proteins for the identification, assessment, prevention, and therapy of ovarian cancer |
| JP2005504517A (ja) | 2001-05-18 | 2005-02-17 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | ＣＤ４４ｖ６特異的抗体 |
| EP1258255A1 (en) | 2001-05-18 | 2002-11-20 | Boehringer Ingelheim International GmbH | Conjugates of an antibody to CD44 and a maytansinoid |
| US20060127894A1 (en) | 2001-08-08 | 2006-06-15 | Incyte Corporation | Protein associated with cell growth, differentiation, and death |
| DE60335129D1 (de) | 2002-07-19 | 2011-01-05 | Morphotek Inc | VERFAHREN ZUR ERZEUGUNG VERBESSERTER ANTIKöRPER PRODUZIERENDER ZELLINIEN MIT VERBESSERTEN WACHSTUMSEIGENSCHAFTEN |
| EP1651675A1 (en) | 2003-08-05 | 2006-05-03 | Morphotek, Inc. | A variant cell surface molecule associated with cancer |
| AU2006223301B2 (en) | 2005-03-10 | 2010-11-04 | Eisai, Inc. | Anti-mesothelin antibodies |
| US20060239910A1 (en) * | 2005-04-22 | 2006-10-26 | Morphotek Inc. | Antibodies with immune effector activity and that internalize in folate receptor alpha-positive cells |
-
2006
- 2006-03-09 AU AU2006223301A patent/AU2006223301B2/en active Active
- 2006-03-09 ES ES10180413T patent/ES2429340T3/es active Active
- 2006-03-09 CA CA2600505A patent/CA2600505C/en active Active
- 2006-03-09 WO PCT/US2006/008598 patent/WO2006099141A2/en not_active Ceased
- 2006-03-09 EP EP10180413.6A patent/EP2322560B1/en active Active
- 2006-03-09 ES ES06737748T patent/ES2386367T3/es active Active
- 2006-03-09 JP JP2008500966A patent/JP4949373B2/ja active Active
- 2006-03-09 EP EP06737748A patent/EP1861425B1/en active Active
- 2006-03-09 US US11/373,546 patent/US7592426B2/en active Active
-
2009
- 2009-08-21 US US12/545,369 patent/US8206710B2/en active Active
-
2011
- 2011-01-24 AU AU2011200251A patent/AU2011200251B2/en active Active
- 2011-12-29 JP JP2011290449A patent/JP5378497B2/ja active Active
-
2012
- 2012-05-21 US US13/476,656 patent/US8481703B2/en active Active
-
2013
- 2013-03-13 US US13/799,766 patent/US8658173B2/en active Active
- 2013-08-13 JP JP2013168325A patent/JP5788443B2/ja active Active
-
2014
- 2014-01-06 US US14/148,011 patent/US9115197B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2014012688A5 (enExample) | ||
| IL273666B (en) | Bispecific molecules immunoreactive with effector cells of the immune system that express a receptor from Actab and an antigen expressed by a virus-infected cell and their uses | |
| JP2014518898A5 (enExample) | ||
| EP3762722A4 (en) | PROTEOMIC ASSAY USING QUANTUM SENSORS | |
| IL254919B (en) | Polypeptide-based shuttle agents for improving the transduction efficiency of polypeptide cargos to the cytosol of target eukaryotic cells, uses thereof, methods and kits relating to same | |
| HUE063272T2 (hu) | Zika-vírus epitópokhoz specifikusan kötõdõ új antitestek és alkalmazásaik | |
| IL264270A (en) | Scalable high recovery methods for producing high yield recombinant adeno-associated viral (raav) vector and recombinant adeno-associated viral (raav) vectors produced thereby | |
| ZA201706011B (en) | Oncolytic adenoviruses coding for bi-specific antibodies and methods and uses related thereto | |
| RU2018132044A (ru) | Антитела против тау | |
| IL267382A (en) | Oncostatin m receptor antigen binding proteins | |
| HUE054180T2 (hu) | Egykarú I. típusú és II. típusú receptorral rendelkezõ fúziós fehérjék, illetve ezek alkalmazásai | |
| EA201791139A1 (ru) | Гетеродимерные антитела, которые связывают cd3 и опухолевые антигены | |
| JP2015536519A5 (enExample) | ||
| HK1217023A1 (zh) | 新型抗体 | |
| CL2013001124A1 (es) | Anticuerpo aislado o una proteína que comprende una porción de enlace de antígeno de un anticuerpo dirigido contra un polipéptido de cd40; composicion farmacéutica que comprende dicho anticuerpo; ácido nucleico que codifica el anticuerpo; vector de clonación; proceso de producción del anticuerpo. | |
| MX2014005728A (es) | Anticuerpos especificos para antigeno de la superficie celular de trofoblasto-2 y sus usos. | |
| EA201591750A1 (ru) | Антитела против b7-h4 и иммуноконъюгаты | |
| JP2018504907A5 (enExample) | ||
| SG10201909716RA (en) | Modified j-chain | |
| JP2014132019A5 (enExample) | ||
| NZ631098A (en) | Anti-hepcidin antibodies and uses thereof | |
| IL273685A (en) | A specific antibody does not. coli with multidrug resistance | |
| JP2015038108A5 (enExample) | ||
| JP2017525355A5 (enExample) | ||
| WO2013152860A3 (en) | Improved antibody light chains |